Matching articles for "AirSupra"
Issue 1716 · November 25, 2024
Drugs for Asthma

The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.

Med Lett Drugs Ther. 2024 Nov 25; 66(1716):185-92 doi:10.58347/tml.2024.1716a
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Issue 1716 · November 25, 2024
Comparison Chart: Some Inhaled Drugs for Treatment of Asthma (online only)

View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma

Med Lett Drugs Ther. 2024 Nov 25; 66(1716):e192-5 doi:10.58347/tml.2024.1716b
View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma
Issue 1698 · March 18, 2024 Free
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma

The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta 2 -agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment…

Med Lett Drugs Ther. 2024 Mar 18; 66(1698):41-3 doi:10.58347/tml.2024.1698a
The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta 2 -agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients ≥18 years old with asthma. Airsupra is the first combination of a SABA and an ICS to become available in the US. It is not approved for use as maintenance therapy.